for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Vertex Receives European CHMP Positive Opinion For Kalydeco (Ivacaftor) For Children And Adolescents With Cystic Fibrosis

May 1 (Reuters) - Vertex Pharmaceuticals Inc:

* RECEIVES EUROPEAN CHMP POSITIVE OPINION FOR KALYDECO (IVACAFTOR) FOR CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS BETWEEN THE AGES 6 MONTHS AND 18 YEARS WITH THE R117H MUTATION IN THE CFTR GENE

* EUROPEAN COMMISSION WILL NOW REVIEW CHMP’S POSITIVE OPINION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up